Answers are grounded in this paper and cite their sources.
Parkinson’s disease (PD) is a neurodegenerative disorder defined by the progressive loss of dopaminergic neurons in the substantia nigra and the accumulation of Lewy body pathology. Although the etiology remains incompletely understood, neuroinflammation has emerged as a key driver of disease progression. Interleukin-33 (IL-33), a dual-function member of the IL-1 family, operates both as a nuclear transcriptional regulator and as an extracellular alarmin. Some clinical studies have reported elevated IL-33 levels in PD patients, particularly at early stages; however, findings across cohorts are heterogeneous, with some studies reporting no or inconsistent changes. Whether circulating IL-33 reliably reflects CNS IL-33/ST2 activity remains uncertain. This review synthesizes current evidence to propose a hypothesis-driven, compartmentalized and context-dependent conceptual framework of IL-33 function in PD. Direct evidence in PD remains limited for several proposed mechanisms, and the framework is intended to generate testable hypotheses rather than to serve as an established model. In the nucleus, IL-33 has been shown in non-PD systems to associate with chromatin and suppress inflammatory transcription via inhibition of NF-κB, AP-1, and PCAF-dependent histone acetylation, while also modulating JAK-STAT and SMAD signaling toward anti-inflammatory or tissue-reparative programs. Whether these nuclear mechanisms operate in human PD astrocytes and microglia has not been directly tested. Nuclear retention of IL-33 may serve dual purposes: maintaining transcriptional homeostasis and limiting uncontrolled extracellular alarmin release. Upon cellular stress or injury, IL-33 is released into the extracellular space. Extracellularly, IL-33 binds to its membrane receptor ST2L (also referred to as membrane ST2 or mST2), initiating immune-dependent pathways—promoting M2 microglial and A2 astrocytic polarization along with Th2 bias—and non-immune pathways that enhance autophagy, chaperone-mediated autophagy (CMA), and TREM2/SYK-mediated phagocytic clearance of α-synuclein aggregates, supported by AKT-driven metabolic empowerment. However, most of these downstream mechanisms have been demonstrated primarily in Alzheimer’s disease models, acute injury models, or non-neural systems, and their relevance to PD/α-synucleinopathy remains to be validated. The soluble decoy receptor sST2 acts as a negative regulator, sequestering IL-33 and blunting these protective effects. We highlight that the spatiotemporal balance between nuclear IL-33, extracellular IL-33/ST2L signaling, and sST2 interference may ultimately determine α-syn clearance and dopaminergic neuronal survival. This review systematically evaluates PD-specific evidence for IL-33, delineates its intracellular versus extracellular actions, and examines the current understanding of IL-33 in relation to α-synuclein homeostasis. Building on this foundation, we propose a biomarker-guided framework for patient stratification and discuss the translational potential—and key challenges—of targeting the IL-33/ST2 axis as a novel disease-modifying strategy for PD.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: